The estimated Net Worth of Eli Hurvitz is at least $5.09 millió dollars as of 12 November 2009. Eli Hurvitz owns over 3,384,502 units of Protalix BioTherapeutics stock worth over $5,094,941 and over the last 16 years Eli sold PLX stock worth over $0.
Eli has made over 1 trades of the Protalix BioTherapeutics stock since 2009, according to the Form 4 filled with the SEC. Most recently Eli exercised 3,384,502 units of PLX stock worth $3,519,882 on 12 November 2009.
The largest trade Eli's ever made was exercising 3,384,502 units of Protalix BioTherapeutics stock on 12 November 2009 worth over $3,519,882. On average, Eli trades about 1,692,251 units every 0 days since 2008. As of 12 November 2009 Eli still owns at least 4,898,982 units of Protalix BioTherapeutics stock.
You can see the complete history of Eli Hurvitz stock trades at the bottom of the page.
Eli's mailing address filed with the SEC is C/O VISHAY INTERTECHNOLOGY, INC., 63 LANCASTER AVENUE, MALVERN, PA, 19355.
Over the last 18 years, insiders at Protalix BioTherapeutics have traded over $46,705,936 worth of Protalix BioTherapeutics stock and bought 4,403,619 units worth $4,673,005 . The most active insiders traders include Phillip Md Et Al Frost Gamm..., Capital Management Lp Camber és Ltd Bio Cell. On average, Protalix BioTherapeutics executives and independent directors trade stock every 88 days with the average trade being worth of $404,231. The most recent stock trade was executed by Dror Bashan on 19 October 2023, trading 64,516 units of PLX stock currently worth $90,322.
protalix is a publicly traded, clinical stage biopharmaceutical company (nyse, tase: plx) focused on the development and commercialization of recombinant therapeutic proteins using its proprietary procellex™ plant cell culture protein expression system. procellex provides a unique platform on which we have established a pipeline of proprietary and biosimilar versions of recombinant therapeutic proteins, relying upon known biological mechanisms of action. protalix's lead product, taliglucerase-alfa is an enzyme replacement therapy for the treatment of gaucher´s disease. protalix has concluded phase iii studies for this drug and is currently undergoing fda review. treatment is currently being provided by protalix to gaucher patients under clinical studies and companionate programs to hundreds of patients worldwide. this product has been licensed to pfizer. protalix's pipeline includes multiple therapeutic protein candidates including: acetylcholinesterase (biodefense); alfa‐galactosidase
Protalix BioTherapeutics executives and other stock owners filed with the SEC include: